Tolvaptan, a highly selective vasopressin V2 receptor antagonist, may be used to treat patients with volume overload and resistant hyponatremia; however, it was found to have no effect on long-term mortality or HF-related morbidity in patients hospitalized with HF (196). This evidence concerns the gene AVPR2 and hydrops fetalis.